Sandra Leung, one of the longest-serving legal chiefs in the pharmaceutical industry, plans to retire from Bristol Myers Squibb in 2025 ... The Princeton, New Jersey-based company whose ...

For over 150 years, Bristol-Myers Squibb (BMS) has been committed to "discover, develop and deliver innovative medicines that help patients prevail over serious diseases." Headquartered in New ...

The new product will help Bristol Myers Squibb compete with biosimilars as Opdivo faces looming patent expiration. Sotyktu, which became the first TYK2 inhibitor to reach the market after its 2022 ...

Last year, Bristol Myers Squibb devoted half a page of its annual report to its diversity, equity and inclusion efforts, ...

Bristol Myers Squibb believes Alzheimer's treatment is the largest potential market for its newly approved schizophrenia drug, Cobenfy, which it expects to eventually generate billions of dollars ...

Bristol Myers (BMY) Squibb announced new five-year results from the POETYK PSO long-term extension, LTE, trial of Sotyktu treatment in adult patients with moderate-to-severe plaque psoriasis.

Old drugs from Bristol Myers Squibb and Pfizer have delivered what the companies and researchers believe could establish them as new standard treatments for certain colorectal cancer patients.

Bristol Myers (BMY) Squibb announced new five-year results from the POETYK PSO long-term extension trial of Sotyktu treatment in adult patients with moderate-to-severe plaque psoriasis.